On March 17, 2022, the Board of Directors (the Board) of Emergent BioSolutions Inc. (the Company) appointed Keith Katkin as a Class I director of the Company, effective as of April 1, 2022 (the Effective Date), with an initial term expiring at the 2022 annual meeting of stockholders. He was also appointed as a member of both the Nominating and Corporate Governance Committee and Strategic Operations Committee of the Board, as of the Effective Date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.08 USD | -5.22% | +15.45% | +111.67% |
May. 02 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
May. 02 | Sector Update: Health Care | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+111.67% | 266M | |
+31.06% | 688B | |
+30.35% | 588B | |
-3.42% | 364B | |
+18.02% | 326B | |
+4.27% | 285B | |
+15.53% | 239B | |
+10.16% | 210B | |
-8.14% | 200B | |
+8.12% | 167B |
- Stock Market
- Equities
- EBS Stock
- News Emergent BioSolutions Inc.
- Emergent BioSolutions Inc. Appoints Keith Katkin as a Class I Director, Member of Both the Nominating and Corporate Governance Committee and Strategic Operations Committee of the Board